Phase I Study to Evaluate the Safety and Effectiveness of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Anti-BCMA CAR-NK Cell therapy-Sichuan Kelun-Biotech Biopharmaceutical (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2021 Status changed from not yet recruiting to recruiting.
- 24 Aug 2021 New trial record